Sevelamer Hydrochloride Exacerbates Metabolic Acidosis in Hemodialysis Patients, Depending on the Dosage

:  Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study o...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic apheresis and dialysis Vol. 11; no. 2; pp. 107 - 113
Main Authors Oka, Yoshinari, Miyazaki, Masashi, Takatsu, Shigeko, Kunitomo, Kei-ichi, Uno, Futoshi, Maruyama, Masanobu, Matsuda, Hiroaki
Format Journal Article
LanguageEnglish
Published Melbourne, Australia Blackwell Publishing Asia 01.04.2007
Subjects
Online AccessGet full text
ISSN1744-9979
1744-9987
DOI10.1111/j.1744-9987.2007.00432.x

Cover

Abstract :  Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty‐six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the ‘sevelamer group’, and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t‐test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose‐dependent manner in hemodialysis patients without hyperchloremia.
AbstractList Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty‐six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the ‘sevelamer group’, and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t ‐test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose‐dependent manner in hemodialysis patients without hyperchloremia.
:  Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty‐six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the ‘sevelamer group’, and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t‐test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose‐dependent manner in hemodialysis patients without hyperchloremia.
Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty-six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the 'sevelamer group', and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t-test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose-dependent manner in hemodialysis patients without hyperchloremia.
Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty-six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the 'sevelamer group', and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t-test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose-dependent manner in hemodialysis patients without hyperchloremia.Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However, sevelamer hydrochloride has been reported to lower the serum bicarbonate level. In the present study, we performed a retrospective study on the potential influences of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients. The subjects were 72 patients who underwent hemodialysis at our hospital. Thirty-six patients taking sevelamer hydrochloride and 36 patients matched for sex, diabetes mellitus, age and duration of dialysis who were not taking sevelamer hydrochloride were studied. We assigned the 36 patients who had been taking sevelamer hydrochloride to the 'sevelamer group', and the 36 patients not taking sevelamer hydrochloride were the control group. Statistical significance was evaluated by a t-test and Pearson's correlation coefficient. In the sevelamer group, the mean levels of bicarbonate, base excess and pH decreased significantly after administration, compared with the values before administration, but in the control group, aggravation of acidosis was not seen. The levels of bicarbonate, base excess and pH after the medication of sevelamer hydrochloride were found to be significantly and negatively correlated with the daily dose of sevelamer hydrochloride. The levels were also found to be significantly and negatively correlated with the cumulative dose of sevelamer hydrochloride; however, the value of the mean levels of chlorine and the anion gap did not increase with sevelamer hydrochloride. Sevelamer hydrochloride caused metabolic acidosis in a dose-dependent manner in hemodialysis patients without hyperchloremia.
Author Oka, Yoshinari
Uno, Futoshi
Kunitomo, Kei-ichi
Maruyama, Masanobu
Miyazaki, Masashi
Matsuda, Hiroaki
Takatsu, Shigeko
Author_xml – sequence: 1
  givenname: Yoshinari
  surname: Oka
  fullname: Oka, Yoshinari
  email: saiwai@io.ocn.ne.jp
  organization: Departments of Surgery and
– sequence: 2
  givenname: Masashi
  surname: Miyazaki
  fullname: Miyazaki, Masashi
  organization: Departments of Surgery and
– sequence: 3
  givenname: Shigeko
  surname: Takatsu
  fullname: Takatsu, Shigeko
  organization: Internal Medicine, Saiwai-cho Memorial Hospital, and
– sequence: 4
  givenname: Kei-ichi
  surname: Kunitomo
  fullname: Kunitomo, Kei-ichi
  organization: Departments of Surgery and
– sequence: 5
  givenname: Futoshi
  surname: Uno
  fullname: Uno, Futoshi
  organization: Department of Digestive Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
– sequence: 6
  givenname: Masanobu
  surname: Maruyama
  fullname: Maruyama, Masanobu
  organization: Department of Digestive Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
– sequence: 7
  givenname: Hiroaki
  surname: Matsuda
  fullname: Matsuda, Hiroaki
  organization: Department of Digestive Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17381531$$D View this record in MEDLINE/PubMed
BookMark eNqNkV1v0zAYhS20iX2wv4B8xRUJ_kqcSAip-2CdNKDSOkDcWLbzZnVJ4mKn0P57Ejp6wQ3zjV_L5zmWzzlBB53vACFMSUqH9WaZUilEUpaFTBkhMiVEcJZunqHj_cXBfpblETqJcUkIY4Lz5-iISl7QjNNjtLiDn9DoFgKebqvg7aLxwVWArzbaQjC6h4g_QK-Nb5zFE-sqH13ErsNTaH3ldLMdzzPdO-j6-Bpfwgq6ynUP2He4XwC-9FE_wAt0WOsmwtnjforu31_NL6bJ7afrm4vJbWIFK1jCJK1NDqTmWZFpMJwzwmmZ59bWVlpiRKmLkhhmSmarTGhhhRGCapHpsiCGn6JXO99V8D_WEHvVumihaXQHfh2VJJzknJeD8OWjcG1aqNQquFaHrfqbzSB4txPY4GMMUCvr-uGbvuuDdo2iRI1lqKUac1Zj5mosQ_0pQ20Gg-Ifg_0b_0ff7tBfroHtkzk1n8yGYcCTHe5iD5s9rsN3lUsuM_Xl47U6P_88_Tb7ytSc_wZqYrC7
CitedBy_id crossref_primary_10_1111_1744_9987_12052
crossref_primary_10_1111_1744_9987_12461
crossref_primary_10_1185_03007995_2013_838551
crossref_primary_10_1080_08860220802381893
crossref_primary_10_1093_ndt_gfq682
crossref_primary_10_1016_j_nephro_2014_04_001
crossref_primary_10_1093_ndt_gfw312
crossref_primary_10_1007_s40265_014_0215_7
crossref_primary_10_1093_ndtplus_sfn034
crossref_primary_10_1016_j_tox_2008_03_012
crossref_primary_10_1111_j_1744_9987_2010_00868_x
crossref_primary_10_1186_1471_2369_14_205
crossref_primary_10_3109_0886022X_2014_976160
crossref_primary_10_1016_j_dialis_2010_07_006
crossref_primary_10_1111_1744_9987_12502
crossref_primary_10_1517_14656566_2010_526107
crossref_primary_10_1016_j_jfms_2009_09_012
crossref_primary_10_1517_14656566_2013_852183
crossref_primary_10_1592_phco_29_5_554
Cites_doi 10.1053/ajkd.1998.v31.pm9531176
10.1046/j.1523-1755.2002.00434.x
10.1111/j.1744-9987.2005.00294.x
10.1016/S0272-6386(12)70364-5
10.1093/ndt/gfh125
10.1046/j.1523-1755.2000.00025.x
10.1081/JDI-200048238
10.1016/S0272-6386(04)00936-9
10.1111/j.1523-1755.2004.09007.x
10.1159/000072822
10.1111/j.1523-1755.2004.00590.x
10.1159/000063307
ContentType Journal Article
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/j.1744-9987.2007.00432.x
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1744-9987
EndPage 113
ExternalDocumentID 17381531
10_1111_j_1744_9987_2007_00432_x
TAP432
ark_67375_WNG_BBVHZPX2_T
Genre article
Clinical Trial
Journal Article
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OC
29Q
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMB
EMOBN
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RX1
SUPJJ
SV3
TEORI
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
~IA
~WT
AAHHS
ACCFJ
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
WRC
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c4282-271fb6e0f3585aeb332031966ccfc7c0b49a890b2b92cd54a4c4b441a45a980b3
IEDL.DBID DR2
ISSN 1744-9979
IngestDate Fri Jul 11 16:54:35 EDT 2025
Wed Feb 19 01:41:46 EST 2025
Wed Oct 01 03:56:25 EDT 2025
Thu Apr 24 23:04:18 EDT 2025
Wed Jan 22 16:30:34 EST 2025
Tue Sep 09 05:30:15 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4282-271fb6e0f3585aeb332031966ccfc7c0b49a890b2b92cd54a4c4b441a45a980b3
Notes ark:/67375/WNG-BBVHZPX2-T
ArticleID:TAP432
istex:F3DAB781B6B982D5BC5DBF656FF1616D9CD33A02
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 17381531
PQID 70306339
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_70306339
pubmed_primary_17381531
crossref_citationtrail_10_1111_j_1744_9987_2007_00432_x
crossref_primary_10_1111_j_1744_9987_2007_00432_x
wiley_primary_10_1111_j_1744_9987_2007_00432_x_TAP432
istex_primary_ark_67375_WNG_BBVHZPX2_T
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2007-04
April 2007
2007-04-00
2007-Apr
20070401
PublicationDateYYYYMMDD 2007-04-01
PublicationDate_xml – month: 04
  year: 2007
  text: 2007-04
PublicationDecade 2000
PublicationPlace Melbourne, Australia
PublicationPlace_xml – name: Melbourne, Australia
– name: Australia
PublicationTitle Therapeutic apheresis and dialysis
PublicationTitleAlternate Ther Apher Dial
PublicationYear 2007
Publisher Blackwell Publishing Asia
Publisher_xml – name: Blackwell Publishing Asia
References Edmung G, Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-82.
Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002;92:499-500.
Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int 2004;66:39-45.
Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14.
Koiwa F, Onoda N, Kato H et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-6.
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:12-28.
Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int 2000;57:1776-7.
Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:661-71.
Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96.
Macroui A, Sonikian MA, Pani IT et al. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7.
Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26.
2004; 65
2004; 66
2004; 44
1990; 15
2004; 19
2002; 62
2000; 57
2005; 9
2002; 92
2005; 27
1998; 31
2003; 42
2003; 23
National Kidney Foundation. (e_1_2_6_9_2) 2003; 42
e_1_2_6_8_2
e_1_2_6_7_2
e_1_2_6_4_2
e_1_2_6_3_2
e_1_2_6_6_2
e_1_2_6_5_2
e_1_2_6_12_2
e_1_2_6_13_2
e_1_2_6_2_2
e_1_2_6_10_2
e_1_2_6_11_2
e_1_2_6_14_2
References_xml – reference: Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int 2000;57:1776-7.
– reference: Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
– reference: Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14.
– reference: Koiwa F, Onoda N, Kato H et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-6.
– reference: Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
– reference: Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96.
– reference: National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:12-28.
– reference: Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26.
– reference: Edmung G, Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-82.
– reference: Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int 2004;66:39-45.
– reference: Macroui A, Sonikian MA, Pani IT et al. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7.
– reference: Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002;92:499-500.
– reference: Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:661-71.
– volume: 42
  start-page: 12
  year: 2003
  end-page: 28
  article-title: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
  publication-title: Am J Kidney Dis
– volume: 15
  start-page: 458
  year: 1990
  end-page: 82
  article-title: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities
  publication-title: Am J Kidney Dis
– volume: 31
  start-page: 607
  year: 1998
  end-page: 17
  article-title: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study
  publication-title: Am J Kidney Dis
– volume: 9
  start-page: 340
  year: 2005
  end-page: 6
  article-title: Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan
  publication-title: Ther Apher Dial
– volume: 62
  start-page: 245
  year: 2002
  end-page: 52
  article-title: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
  publication-title: Kidney Int
– volume: 27
  start-page: 143
  year: 2005
  end-page: 7
  article-title: Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride
  publication-title: Ren Fail
– volume: 65
  start-page: 1914
  year: 2004
  end-page: 26
  article-title: Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study)
  publication-title: Kidney Int
– volume: 57
  start-page: 1776
  year: 2000
  end-page: 7
  article-title: Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder
  publication-title: Kidney Int
– volume: 66
  start-page: 39
  year: 2004
  end-page: 45
  article-title: Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications
  publication-title: Kidney Int
– volume: 44
  start-page: 661
  year: 2004
  end-page: 71
  article-title: Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
  publication-title: Am J Kidney Dis
– volume: 23
  start-page: 307
  year: 2003
  end-page: 14
  article-title: The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients
  publication-title: Am J Nephrol
– volume: 19
  start-page: 1489
  year: 2004
  end-page: 96
  article-title: Determinants of progressive vascular calcification in haemodialysis patients
  publication-title: Nephrol Dial Transplant
– volume: 92
  start-page: 499
  year: 2002
  end-page: 500
  article-title: Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients
  publication-title: Nephron
– ident: e_1_2_6_3_2
  doi: 10.1053/ajkd.1998.v31.pm9531176
– volume: 42
  start-page: 12
  year: 2003
  ident: e_1_2_6_9_2
  article-title: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
  publication-title: Am J Kidney Dis
– ident: e_1_2_6_4_2
  doi: 10.1046/j.1523-1755.2002.00434.x
– ident: e_1_2_6_13_2
  doi: 10.1111/j.1744-9987.2005.00294.x
– ident: e_1_2_6_2_2
  doi: 10.1016/S0272-6386(12)70364-5
– ident: e_1_2_6_6_2
  doi: 10.1093/ndt/gfh125
– ident: e_1_2_6_12_2
  doi: 10.1046/j.1523-1755.2000.00025.x
– ident: e_1_2_6_8_2
  doi: 10.1081/JDI-200048238
– ident: e_1_2_6_10_2
  doi: 10.1016/S0272-6386(04)00936-9
– ident: e_1_2_6_7_2
  doi: 10.1111/j.1523-1755.2004.09007.x
– ident: e_1_2_6_5_2
  doi: 10.1159/000072822
– ident: e_1_2_6_14_2
  doi: 10.1111/j.1523-1755.2004.00590.x
– ident: e_1_2_6_11_2
  doi: 10.1159/000063307
SSID ssj0022433
Score 1.8594898
Snippet :  Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients....
Sevelamer hydrochloride, as a phosphate binder that contains neither aluminum nor calcium, is expected to improve the prognosis of dialysis patients. However,...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 107
SubjectTerms Acidosis - drug therapy
Bicarbonate
Bicarbonates - analysis
Chelating Agents - therapeutic use
Dose-Response Relationship, Drug
Female
Hemodialysis
Humans
Hydrogen-Ion Concentration
Male
Metabolic acidosis
Middle Aged
Non-anion gap acidosis
Polyamines - therapeutic use
Renal Dialysis - methods
Sevelamer
Sevelamer hydrochloride
Title Sevelamer Hydrochloride Exacerbates Metabolic Acidosis in Hemodialysis Patients, Depending on the Dosage
URI https://api.istex.fr/ark:/67375/WNG-BBVHZPX2-T/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1744-9987.2007.00432.x
https://www.ncbi.nlm.nih.gov/pubmed/17381531
https://www.proquest.com/docview/70306339
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 1744-9979
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1744-9987
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022433
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELemIU28ABtfAbb5Ae2JVEns2Mlj9xkhdapYBxUvlu04ouqWoKaVCn89d0la1mkPE-LNL-fE5zvf7-z7IORj6OJcxFHiM8cDn6e59hOXC59LHScFOAipxQv9waXIrvnncTzu4p8wF6atD7G-cEPNaM5rVHBt6k0ll5z74C7IVSVCzqIe4smQica7-rKuJAWGqukq35HI9H5QzwMTbViqJ8j05UMwdBPVNmbp_DmZrhbURqNMe4u56dnf92o9_p8VvyDPOvRK-6247ZItV-6RnUH3Pv-S_LjCGCR962Y0-5VjNy4M8MsdPVtqCxuIwJYO3Bwk72Ziad9O8qqe1HRS0szdVpjEghVS6LCt9lp_oqdNk16wr7QqKYBVelphKNwrcn1-NjrJ_K6Xg2_BwcEMoLAwwgUFA_9EgwfPIsyfEsLawkobGJ7qJA1MZNLI5jHX3HIDUE3zWKdJYNhrsl1WpXtLqMPEAZPkMBEHdxSGSSGATmhWJKGWHpGrfVO2K3SO_TZu1B2HBxipkJHYhhNf4IGRaumRcE35sy328Qiao0Y01gR6NsVgORmrb5cX6vj4a_Z9OI7UyCOHK9lRoML4LqNLVy1qhYeuYCz1yJtWpP5-XAKgglPSI3EjGI_-KzXqD2Hw7h_p3pOn7R02Rih9INvz2cLtA_iam4NGrf4A0NkehQ
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED-hTQJeGJ8j42N-QDyRKk0cO3ns2EaAtaqgg4oXy3YcUa1LUD-kwl_PXZIWOu1hQrz55ZzYvvP97nwfAK-6Ls5FHCZ-5Hjg8zTXfuJy4XOp46RAAyG15NDvD0R2zj-M43HbDohyYZr6EBuHG0lGfV-TgJNDelvKJec-2gtyXYqQR2EHAeUuF2i2EEL6tKklhaqq7ivf0sj0aljPNTNt6apd2vbVdUB0G9fWiul0D6brJTXxKBed5cJ07K8r1R7_05rvw70WwLJew3EP4JYrH8LtfvtE_wi-f6YwJH3pZiz7mVNDLorxyx07WWmLZ0jYlvXdAplvOrGsZyd5NZ_M2aRkmbusKI-FiqSwYVPwdf6GHdd9elHFsqpkiFfZcUXRcI_h_PRk9Dbz23YOvkUbh5KAuoURLigiNFE0GvFRSClUQlhbWGkDw1OdpIEJTRraPOaaW24QrWke6zQJTPQEdsqqdE-BOcodMEmOE3G0SHGYFALphI6KpKulB3J9cMq2tc6p5cZU_WXz4EYq2kjqxEmP8LiRauVBd0P5o6n3cQOa1zVvbAj07ILi5WSsvg7eqaOjL9m34ThUIw8O18yjUIrpaUaXrlrOFd27IopSD_YbnvrzcYmYCi9KD-KaM278V2rUG-Lg4B_pDuFONuqfqbP3g4_P4G7j0qaApeews5gt3QvEYgvzspax39R8IqY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED-hTZp4gY2vBRjzA-KJVGliJ85jt66Ej1YVdFDxYjmOI6p1ydQPqeOv312SFjrtYUK8-eWc-Hzn-519HwBv21ZkofClG1juuTzOtCttFro80kLm6CDEhi70-4MwOeefxmLctAOiXJi6PsTmwo00ozqvScHtVZZva3nEuYv-QrQuRcgDv4WAcpeLWFJ8X_frppYUmqqqr3xDE8W3w3rumGnLVu0S21d3AdFtXFsZpt5jmK6XVMejXLSWi7Rlft-q9vif1rwPjxoAyzq1xB3AA1s8gb1-80T_FH59ozAkfWlnLLnOqCEXxfhllp2ttME9JGzL-naBwjedGNYxk6ycT-ZsUrDEXpaUx0JFUtiwLvg6f8-6VZ9eNLGsLBjiVdYtKRruGZz3zkanidu0c3AN-jiUBNTO09B6eYAuikYnPvAphSoMjclNZLyUx1rGXuqnsW8ywTU3PEW0prnQsfTS4DnsFGVhD4FZyh1IZYYTcfRIcSjzEOlCHeSyrSMHovXGKdPUOqeWG1P1l8-DjFTESOrESY_wyEi1cqC9obyq633cg-ZdJRsbAj27oHi5SKgfgw_q5OR78nM49tXIgeO18CjUYnqa0YUtl3NF524YBLEDL2qZ-vPxCDEVHpQOiEoy7v1XatQZ4uDlP9Idw96w21NfPg4-v4KH9Y02xSu9hp3FbGmPEIot0jeVit0AS0IiKg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sevelamer+Hydrochloride+Exacerbates+Metabolic+Acidosis+in+Hemodialysis+Patients%2C+Depending+on+the+Dosage&rft.jtitle=Therapeutic+apheresis+and+dialysis&rft.au=Oka%2C+Yoshinari&rft.au=Miyazaki%2C+Masashi&rft.au=Takatsu%2C+Shigeko&rft.au=Kunitomo%2C+Kei%E2%80%90ichi&rft.date=2007-04-01&rft.issn=1744-9979&rft.eissn=1744-9987&rft.volume=11&rft.issue=2&rft.spage=107&rft.epage=113&rft_id=info:doi/10.1111%2Fj.1744-9987.2007.00432.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1744_9987_2007_00432_x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1744-9979&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1744-9979&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1744-9979&client=summon